Education
About Us
Working with TipRanks
Follow Us
InnoCare Pharma Ltd. (HK:9969)
:9969
9969 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$4.40 - HK$20.44
Previous CloseN/A
Volume2.17M
Average Volume (3M)18.37M
Market Cap
HK$29.33B
Enterprise ValueHK$4.71B
Total Cash (Recent Filing)HK$6.22B
Total Debt (Recent Filing)HK$1.57B
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,496,284,200
10 Day Avg. Volume16,493,173
30 Day Avg. Volume18,371,670
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.87Price Target Upside4.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceInnoCare reported net income of RMB14mn, underpinned by orelabrutinib’s strong sales and a US$8.75mn upfront payment from out-licensing.
Financial StabilityInnoCare maintained a robust cash position of RMB7.8bn, providing ample capital for R&D initiatives.
Product ApprovalOrelabrutinib remains the only BTK inhibitor approved and included in the NRDL for MZL in China, the second-largest subtype of NHL.
Revenue GrowthInnoCare delivered solid results, with revenue reaching RMB381mn, supported by sustained uptake in MZL.
Bears Say
Market CompetitionTwo TYK2 inhibitors, ICP-322 and ICP-488, show differentiated efficacy and competitive results in treating atopic dermatitis and psoriasis.
Market DynamicsAutoimmune pipeline offers broad long-term upside, viewed as a key pillar of future growth alongside its oncology franchise.
InnoCare Pharma Ltd. News
9969 FAQ
What was InnoCare Pharma Ltd.’s price range in the past 12 months?
InnoCare Pharma Ltd. lowest stock price was HK$4.40 and its highest was HK$20.44 in the past 12 months.
What is InnoCare Pharma Ltd.’s market cap?
InnoCare Pharma Ltd.’s market cap is HK$29.33B.
When is InnoCare Pharma Ltd.’s upcoming earnings report date?
InnoCare Pharma Ltd.’s upcoming earnings report date is Nov 17, 2025 which is in 90 days.
How were InnoCare Pharma Ltd.’s earnings last quarter?
InnoCare Pharma Ltd. released its earnings results on Aug 19, 2025. The company reported -HK$0.022 earnings per share for the quarter, beating the consensus estimate of -HK$0.098 by HK$0.076.
Is InnoCare Pharma Ltd. overvalued?
According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued.
Does InnoCare Pharma Ltd. pay dividends?
InnoCare Pharma Ltd. does not currently pay dividends.
What is InnoCare Pharma Ltd.’s EPS estimate?
InnoCare Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCare Pharma Ltd. have?
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding.
What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
InnoCare Pharma Ltd. reported an EPS of -HK$0.022 in its last earnings report, beating expectations of -HK$0.098. Following the earnings report the stock price went down -0.21%.
Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
Currently, no hedge funds are holding shares in HK:9969
InnoCare Pharma Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$20.87 (4.35% Upside)
HK$20.87 (4.35% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
337.50%
12-Months-Change
Fundamentals
Return on Equity
-6.35%
Trailing 12-Months
Asset Growth
-8.34%
Trailing 12-Months
Company Description
InnoCare Pharma Ltd.
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
9969 Stock 12 Month Forecast
Average Price Target
HK$20.87
▲(4.35% Upside)
Technical Analysis
Everest Medicines Ltd.
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―
Ascentage Pharma Group International
―
Ownership Overview
―
Insiders
1.93%
Mutual Funds
― Other Institutional Investors
96.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---